JPRN-UMIN000015904已完成未知
A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS - A prospective, multicenter clinical study of the MDT-4113 for the treatment of patients with Severe, Progressive, Life-threatening Early Onset Pediatric Scoliosis:EOS
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 10years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Has active infection and/or has significant infectious risk 2. Is diagnosed to allergy or hypersensitivity to metal or is suspect to metal allergy/hypersensitivity 3. General anesthesia is NOT appropriate 4. Operated on spinal fusion with implant(s) 5. Had participated other clinical trial during the last 3 months 6. Has convulsion (If an investigator decides that a patient is not appropriate to enter this study) 7. Has untreated syringomyelia, spinal deformity or spinal cord tumor 8. Reaches skeletal maturity 9. Has inadequate tissue coverage over the operative site 10. Has hypophrenia (If an investigator decides that a patient is not appropriate to enter this study.) 11. Has rib fusion 12. His/her parent or legal guardian has not signed the Informed Consent form
研究者
相似试验
已完成
不适用
Prospective multicenter study on efficacy of the mediastinal and para-aortic lymph node dissection for esophagogastric junction cancer.Esophagogastric junction cancerJPRN-UMIN000013205Working Group of Japanese Gastric Cancer Association and Japan Esophageal Society371
进行中（未招募）
1 期
Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)MedDRA version: 20.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004689-11-GBMorphoSys AG330
进行中（未招募）
1 期
Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentRelapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)MedDRA version: 21.0Level: PTClassification code 10012821Term: Diffuse large B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004689-11-DEMorphoSys AG450
进行中（未招募）
1 期
Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentEUCTR2014-004689-11-ROMorphoSys AG330
进行中（未招募）
1 期
Open-label, randomised trial to evaluate the efficacy and safety of MOR00208 with bendamustine versus rituximab with bendamustine in adult patients with a cancer of B cells, a type of white blood cell responsible for producing antibodies, which has returned after a period of improvement or that has proved resistant, or does not respond to, treatmentEUCTR2014-004689-11-CZMorphoSys AG330